Warrants of series TO 1 were subscribed to approximately 97.4 percent and Qlife Holding receives approximately SEK 38.1 million
Qlife Holding AB (“Qlife” or the “Company) today announces the outcome of the exercise of the warrants of series TO 1 that were issued in connection with the Company’s issue of units in February 2020. In total, 4,356,436 warrants of series TO 1 were exercised, corresponding to approximately 97.4 percent of the total number of outstanding warrants, for subscription of 2,178,218 shares at a subscription price of SEK 17.50 per share. Through the exercise of the warrants, Qlife will receive approximately SEK 38.1 million before issuing costs amounting to approximately SEK 1.4 million.
The exercise period for the warrants of series TO 1 took place from May 3, 2021 up to and including May 31, 2021. The subscription price per share for the exercise of warrants of series TO 1 amounted to SEK 17.50.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares and share capital
Through the exercise of the warrants of series TO 1, where two (2) warrants entitled to subscription of one (1) share, the number of shares in Qlife increases by 2,178,218 shares, from 13,306,709 to a total of 15,484,927 shares. The share capital will increase by SEK 174,257.44, from SEK 1,064,536.72 to SEK 1,238,794.16.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Qlife. An offer to the persons concerned to subscribe for units consisting of shares and warrants series TO 1 in Qlife has only been made through the prospectus that Qlife published on January 17, 2020.
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-06-2021 08:00 CET.
Mette Gross, Chair Qlife Holding AB
Tel. No.: +46 (0)73-517 85 25
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: email@example.com).